[{"orgOrder":0,"company":"Janssen-Cilag","sponsor":"Argenx","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Janssen Affiliate Cilag GmbH International Discontinues Collaboration and License Agreement with argenx for Cusatuzumab","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","year":"2021","type":"Termination","leadProduct":"Cusatuzumab","moa":"CD70","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II","graph3":"Janssen-Cilag","amount2":0,"therapeuticAreaNew":"Oncology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","productSubType":"","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Janssen-Cilag \/ Argenx","highestDevelopmentStatusID":"8","companyTruncated":"Janssen-Ci.."}]

Find Clinical Drug Pipeline Developments & Deals by Janssen-Cilag

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Boulder Peptide 2024
                          Not Confirmed
                          Boulder Peptide 2024
                          Not Confirmed

                          Details : The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.

                          Product Name : JNJ-74494550

                          Product Type : Large molecule

                          Upfront Cash : Undisclosed

                          June 07, 2021

                          Lead Product(s) : Cusatuzumab,Azacitidine

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Partner/Sponsor/Collaborator : Argenx

                          Deal Size : Undisclosed

                          Deal Type : Termination

                          blank